Dr. Sam Ringle

EU Regional Lead of CSL Behring’s ex-vivo and in-vivo gene therapy portfolio within the therapeutic areas of hematology and immunology

Responsible Manager and EU Regulatory Lead for two early stage ex vivo gene therapy programs within CSL Behring’s immunology portfolio Responsible Manager and EU Regional Lead for CSL Behring’s recombinant factor IX product IDELVION - Main contact person for EMA during renewal procedure, extension application, variations, PSURs, PIP compliance check, PIP annual report, ODD annual report and Post-Authorization Measures

+ Life-cycle management of CSL Behring’s EU hyperimmune portfolio (Tetagam P, Beriglobin, Hepatitis B Immunoglobulin P Behring, Berirab P) + EU Regional Lead of a recombinant development product within CSL Behring’s immunology portfolio + EU Affiliate Coordination - Communicating and implementing regulatory submission strategies developed within the EU Region department - Main contact person for CSL Behring’s EU Regulatory Affiliates located in ten different subsidiaries

Working as a PhD student in the group of Prof. Gunter Meister. During my PhD I was working on dissecting the regulatory role of mRNA methylation within eukaryotic cells. Hereby, I applied a range of basic molecular biological and biochemistry techniques.

RNA Biology and Gene regulation

Genetics / Epigenetics , Biochemistry , Cell biology